ResMed Completes $340M Acquisition of Noctrix Health for Restless Legs Syndrome Therapy
Summary
ResMed has completed its $340 million acquisition of Noctrix Health, a medical device company developing wearable neuromodulation therapies for chronic neurological and sleep-related conditions. The acquisition adds Noctrix's Nidra Tonic Motor Activation therapy to ResMed's portfolio, expanding beyond core sleep apnea and respiratory care businesses into Restless Legs Syndrome treatment. Nidra is the first FDA De Novo classified, non-invasive, non-pharmacologic therapy for moderate-to-severe RLS, with 10 peer-reviewed publications and inclusion in American Academy of Sleep Medicine clinical practice guidelines.
Why it matters
This acquisition represents a major exit in the neuromodulation space and validates the commercial potential of wearable neurotherapeutics for sleep disorders. ResMed's move into RLS through acquisition rather than internal R&D signals that larger medtech companies view neuromodulation startups as attractive bolt-ons. For the neurotech ecosystem, a $340M exit provides a meaningful return benchmark and demonstrates that non-invasive neuromodulation devices can reach commercial scale.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial